NE-ADJUVANCE-TECH
25.1.2022 15:37:12 CET | Business Wire | Press release
Adjuvance Technologies Inc., a privately-held clinical-stage biopharmaceutical company developing next generation saponin adjuvants and vaccines for infectious disease and immuno-oncology, today announced that Philip Krause, MD, will take on a strategic consulting role with the organization as it advances its vaccine development portfolio. Dr. Krause recently served as the Deputy Director, Office of Vaccines Research and Review of the US Food and Drug Administration (FDA) Center for Biologics Evaluation and Research.
“The deep scientific, regulatory and vaccine development experience that Phil brings to Adjuvance will be instrumental in efficiently developing our shingles vaccine candidate and our pipeline anchored on the next-generation saponin adjuvant TQL-1055,” noted Dr. Tyler Martin, Adjuvance CEO, President and Chairman. “I am thrilled to enhance the company’s expertise with such a well-respected scientist.”
Dr. Krause previously had a 30-year career in the FDA where he made major contributions in design of clinical trials, molecular virology and immunology, and the regulation and development of vaccines. He will provide strategic consulting on vaccine development, US and international regulatory affairs, clinical trial design and evaluation, virology and immunology and global health.
Dr. Krause said, “I look forward to this opportunity to provide advice and counsel to the Adjuvance leadership team on the development of their innovative saponin adjuvant platform, and their lead vaccine candidates.”
About TQL-1055 : TQL-1055 is a rationally designed, semi-synthetic analogue of the QS-21 saponin adjuvant, which is used in the currently available shingles vaccine. Saponin adjuvants are potent immune stimulators and important components of licensed, currently marketed, and clinically advanced infectious disease vaccines. The usefulness of saponin adjuvants has been constrained by dose-limiting tolerability and manufacturing challenges. TQL-1055 is designed to have improved tolerability and to provide the same strong immune response as QS21 and has shown favorable tolerability in a Phase 1 clinical trial. Adjuvance is designing new combination adjuvants, with TQL-1055 as the foundation, to produce different types of immune responses.
About Shingles : Shingles (also known as herpes zoster) is a painful rash that develops, often on the face or torso, and has the potential complication of pain that can last for months or even years. Vaccination against shingles is recommended in the United States and many countries for older adults and people with weak immune systems, resulting in a market value of over $2.0 billion in 2020. Available shingles vaccines contain the saponin adjuvant QS-21 and the toll-like receptor (TLR) 4 agonist adjuvant monophosphoryl lipid A (MPL), known together as the AS01 adjuvant. The adjuvanted shingles vaccine is highly effective, but can cause short-term adverse events more intense than other vaccines. About 1 out of 6 people who got the available shingles vaccine experienced side effects that prevented them from doing regular activities. Symptoms went away on their own in about 2 to 3 days.
About Adjuvance Technologies : Adjuvance Technologies is a privately-held, clinical-stage biopharmaceutical company dedicated to making vaccines better through fundamental breakthroughs in adjuvant design, vaccine development, and manufacturing. Adjuvance creates and manufactures next generation proprietary adjuvants as the foundation of its vaccine pipeline and for other developers through licensing partnerships. Our lead vaccine candidate against shingles aims to provide a better patient experience including improved tolerability for the recipient and the same protection against disease.
Headquartered in Lincoln, Nebraska, the company has received grant funding from the National Institutes of Health (NIH) and closed a Series A investment by Morningside Venture Investments. For more information, visit www.adjuvancetechnologies.com and connect with us on Twitter and LinkedIn .
View source version on businesswire.com: https://www.businesswire.com/news/home/20220125005493/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Phasecraft Joins DARPA’s Quantum Benchmarking Initiative3.3.2026 16:49:00 CET | Press release
Company will leverage its proprietary software and algorithms to inform verification and validation efforts Phasecraft, the world’s leading quantum algorithms company, today announced it has commenced work on the University of Maryland’s Applied Research Laboratory for Intelligence and Security’s (ARLIS) new contract to support the Defense Advanced Research Projects Agency’s (DARPA) ongoing Quantum Benchmarking Initiative (QBI). QBI’s goal is to assess if it is possible to achieve utility-scale quantum computing by 2033. Phasecraft joins the contract as a technical expert and will leverage its proprietary software and quantum algorithms to develop optimized estimates of resource requirements for quantum applications to inform the U.S. Government (USG) verification and validation efforts. Evaluating Progress Towards Quantum Utility While the cutting-edge quantum hardware selected for QBI inches closer to commercial utility, ultra-efficient quantum algorithms like those Phasecraft develo
Xsolla SDK Now Available for Game Developers Globally3.3.2026 15:48:00 CET | Press release
Backed by 20 years of Game Commerce Innovation, Xsolla SDK is a Platform Agnostic Software Development Kit that Game Developers Can Now Use to Seamlessly Expand Monetization Across Mobile, PC, and Web Xsolla, a global video game commerce company that has helped developers launch, grow, and monetize their games, today announced the availability of Xsolla SDK, a unified, cross-platform software development kit that consolidates the company's PC, mobile, and web monetization tools into a single download. Launching at GDC Festival of Games 2026, the Xsolla SDK introduces built-in Payments, Login, Catalog, and Offerwall integration for developers, enabling them to configure their pricing and inventory once and deploy across every supported platform with no reconfiguration required. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260303075966/en/ Graphic: Xsolla Xsolla is building all the things to help developers monetize cross-pl
ZAPI GROUP to Showcase New Electrification Solutions at ConExpo/AGG 20263.3.2026 15:03:00 CET | Press release
Electrification leader demonstrates expanded low & high voltage capabilities at North America’s largest construction show ZAPI GROUP, a global leader in electrification, will demonstrate new solution capabilities within industrial vehicle electrification at ConExpo/AGG, taking place (March 3-7) in Las Vegas. As electrified construction equipment evolves to include larger, more demanding applications, the group has developed new higher-powered on-board DC/DC converters, inverters, electrical motors, and battery chargers to support those performance requirements, while combining additional utility functions within a compact form-factor. Featured solutions include: For motive power applications, a third-generation high-voltage inverter (ACH3) with customizable control software for enhanced performance, and a permanent magnet, electrical motor solution (IMI), with an integrated, liquid-cooled power-electronic inverter. On the battery-charging front, there will be new high-voltage, high-pow
Carta Launches CRM with Acquisition of ListAlpha3.3.2026 15:01:00 CET | Press release
Acquisition expands Carta’s AI-first ERP for private capital, creating an institutional-grade platform for deal teams and fundraising professionals to increase capital velocity Carta, the world’s first fully interconnected system for private capital, today announced it has acquired ListAlpha, the AI-powered CRM and relationship intelligence platform. The acquisition marks the launch of Carta CRM, a major expansion of the Carta ERP that further unifies front-to-back office workflows for the private markets. Private equity and venture capital firms have long operated in a fragmented way, keeping relationship context in siloed CRMs while fund performance data remains trapped in back-office ledgers. This information silo quietly erodes clarity for deal teams and GPs, slowing down teams and decreasing capital velocity. By integrating ListAlpha’s specialized CRM directly into the Carta ecosystem, firms can unify front-office intelligence with back-office execution on a single platform. Effec
Flexitech Chooses Rimini Street to Extend the Life of its SAP ECC, Accelerate Compliance and Fund Innovation3.3.2026 15:00:00 CET | Press release
Rimini Support™ for SAP helps French brake parts manufacturer avoid unwanted move to RISE with SAP, strengthen security and compliance readiness and reinvest freed capital into R&D and modernization initiatives Rimini Street, Inc. (Nasdaq: RMNI), the Software Support and Agentic AI ERP Company™, and the leading third-party support provider for Oracle, SAP and VMware software, today announced Flexitech, a French manufacturer of brake and cooling hose solutions for the global automotive industry, has selected Rimini Support™ for SAP to strengthen security, accelerate compliance readiness and free budget for innovation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260303263951/en/ Flexitech Chooses Rimini Street to Extend the Life of its SAP ECC, Accelerate Compliance and Fund Innovation Rimini Support™ Enables Stability, Compliance and Strategic Reinvestment Flexitech relies on a stable SAP ECC 6 environment to support its w
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom